Literature DB >> 28158482

Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes.

Ryan Vandrey1, Evan S Herrmann2, John M Mitchell3, George E Bigelow1, Ronald Flegel4, Charles LoDico4, Edward J Cone1.   

Abstract

Most research on cannabis pharmacokinetics has evaluated inhaled cannabis, but oral ("edible") preparations comprise an increasing segment of the cannabis market. To assess oral cannabis pharmacokinetics and pharmacodynamics, healthy adults (N = 6 per dose) were administered cannabis brownies containing 10, 25 or 50 mg 9-tetrahydrocannabinol (THC). Whole blood and oral fluid specimens were obtained at baseline and then for 9 days post-exposure; 6 days in a residential research setting and 3 days as outpatients. Measures of subjective, cardiovascular and performance effects were obtained at baseline and for 8 h post-ingestion. The mean Cmax for THC in whole blood was 1, 3.5 and 3.3 ng/mL for the 10, 25 and 50 mg THC doses, respectively. The mean maximum concentration (Cmax) and mean time to maximum concentration (Tmax) of 11-OH-THC in whole blood were similar to THC. Cmax blood concentrations of THCCOOH were generally higher than THC and had longer Tmax values. The mean Tmax for THC in oral fluid occurred immediately following oral dose administration, and appear to reflect local topical residue rather than systemic bioavailbility. Mean Cmax oral fluid concentrations of THCCOOH were lower than THC, erratic over time and mean Tmax occurred at longer times than THC. The window of THC detection ranged from 0 to 22 h for whole blood (limit of quantitation (LOQ) = 0.5 ng/mL) and 1.9 to 22 h for oral fluid (LOQ = 1.0 ng/mL). Subjective drug and cognitive performance effects were generally dose dependent, peaked at 1.5-3 h post-administration, and lasted 6-8 h. Whole blood cannabinoid concentrations were significantly correlated with subjective drug effects. Correlations between blood cannabinoids and cognitive performance measures, and between oral fluid and all pharmacodynamic outcomes were either non-significant or not orderly by dose. Quantitative levels of cannabinoids in whole blood and oral fluid were low compared with levels observed following inhalation of cannabis. The route of administration is important for interpretation of cannabinoid toxicology. Published by Oxford University Press 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28158482      PMCID: PMC5890870          DOI: 10.1093/jat/bkx012

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  24 in total

1.  Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products.

Authors:  Ryan Vandrey; Jeffrey C Raber; Mark E Raber; Brad Douglass; Cameron Miller; Marcel O Bonn-Miller
Journal:  JAMA       Date:  2015 Jun 23-30       Impact factor: 56.272

2.  Edibles: for experts only? Ingesting marijuana, as opposed to smoking it, has come a long way since the days of homemade pot brownies.

Authors:  Suzanne Weiss
Journal:  State Legis       Date:  2015-03

3.  Patterns of medical marijuana use among individuals sampled from medical marijuana dispensaries in los angeles.

Authors:  Christine E Grella; Luz Rodriguez; Tina Kim
Journal:  J Psychoactive Drugs       Date:  2014 Oct-Dec

4.  Calculating correlation coefficients with repeated observations: Part 1--Correlation within subjects.

Authors:  J M Bland; D G Altman
Journal:  BMJ       Date:  1995-02-18

5.  Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration.

Authors:  Madeleine J Swortwood; Matthew N Newmeyer; Maria Andersson; Osama A Abulseoud; Karl B Scheidweiler; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2016-10-13       Impact factor: 3.345

6.  Increased susceptibility to memory intrusions and the Stroop interference effect during acute marijuana intoxication.

Authors:  W D Hooker; R T Jones
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 7.  Cannabis effects on driving skills.

Authors:  Rebecca L Hartman; Marilyn A Huestis
Journal:  Clin Chem       Date:  2012-12-07       Impact factor: 8.327

8.  Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.

Authors:  Garry Milman; Mateus M Bergamaschi; Dayong Lee; Damodara R Mendu; Allan J Barnes; Ryan Vandrey; Marilyn A Huestis
Journal:  Ther Drug Monit       Date:  2014-04       Impact factor: 3.681

9.  Psychomotor performance, subjective and physiological effects and whole blood Δ⁹-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis.

Authors:  David M Schwope; Wendy M Bosker; Johannes G Ramaekers; David A Gorelick; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2012-05-15       Impact factor: 3.367

10.  Tetrahydrocannabinol and two of its metabolites in whole blood using liquid chromatography-tandem mass spectrometry.

Authors:  Cynthia Coulter; Elizabeth Miller; Katherine Crompton; Christine Moore
Journal:  J Anal Toxicol       Date:  2008-10       Impact factor: 3.367

View more
  54 in total

1.  Pharmacokinetics of Cannabis Brownies: A Controlled Examination of Δ9-Tetrahydrocannabinol and Metabolites in Blood and Oral Fluid of Healthy Adult Males and Females.

Authors:  Tory R Spindle; Edward J Cone; Evan S Herrmann; John M Mitchell; Ronald Flegel; Charles LoDico; George E Bigelow; Ryan Vandrey
Journal:  J Anal Toxicol       Date:  2020-10-12       Impact factor: 3.367

2.  Pharmacokinetic Characterization of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults.

Authors:  Nicolas J Schlienz; Edward J Cone; Evan S Herrmann; Natalie A Lembeck; John M Mitchell; George E Bigelow; Ronald Flegel; Charles P LoDico; Eugene D Hayes; Ryan Vandrey
Journal:  J Anal Toxicol       Date:  2018-05-01       Impact factor: 3.367

3.  Human Pharmacokinetic Parameters of Orally Administered Δ9-Tetrahydrocannabinol Capsules Are Altered by Fed Versus Fasted Conditions and Sex Differences.

Authors:  Stephanie Lunn; Patrick Diaz; Shannon O'Hearn; Shaina P Cahill; Alexia Blake; Kelly Narine; Jason R B Dyck
Journal:  Cannabis Cannabinoid Res       Date:  2019-12-06

Review 4.  Pharmacological evidence of medicinal cannabis in oncology: a systematic review.

Authors:  Danielle Brown; Michael Watson; Janet Schloss
Journal:  Support Care Cancer       Date:  2019-05-06       Impact factor: 3.603

Review 5.  The why behind the high: determinants of neurocognition during acute cannabis exposure.

Authors:  Johannes G Ramaekers; Natasha L Mason; Lilian Kloft; Eef L Theunissen
Journal:  Nat Rev Neurosci       Date:  2021-05-27       Impact factor: 34.870

6.  The potential impact of cannabis legalization on the development of cannabis use disorders.

Authors:  Alan J Budney; Jacob T Borodovsky
Journal:  Prev Med       Date:  2017-06-28       Impact factor: 4.018

7.  Trends in marijuana edible consumption and perceptions of harm in a cohort of young adults.

Authors:  Beth A Reboussin; Kimberly G Wagoner; Erin L Sutfin; Cynthia Suerken; Jennifer Cornacchione Ross; Kathleen L Egan; Stephannie Walker; Renee M Johnson
Journal:  Drug Alcohol Depend       Date:  2019-10-23       Impact factor: 4.492

Review 8.  Cannabis regulatory science: risk-benefit considerations for mental disorders.

Authors:  Jacob T Borodovsky; Alan J Budney
Journal:  Int Rev Psychiatry       Date:  2018-05-29

Review 9.  Aging circadian rhythms and cannabinoids.

Authors:  Erik L Hodges; Nicole M Ashpole
Journal:  Neurobiol Aging       Date:  2019-03-25       Impact factor: 4.673

10.  Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)-a pilot study.

Authors:  Lanfranco Pellesi; Manuela Licata; Patrizia Verri; Daniele Vandelli; Federica Palazzoli; Filippo Marchesi; Maria Michela Cainazzo; Luigi Alberto Pini; Simona Guerzoni
Journal:  Eur J Clin Pharmacol       Date:  2018-07-06       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.